The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Medicine (Baltimore). 2024 Sep 13;103(37):e39613. doi: 10.1097/MD.0000000000039613.
The rate of incidence of metabolic dysfunction-related fatty liver disease (MAFLD) has rapidly increased globally in recent years, but early diagnosis is still a challenge. The purpose of this systematic review and meta-analysis is to identify visfatin for early diagnosis of MAFLD.
We strictly adhered to the relevant requirements of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The systematic search was conducted in 7 sources (PubMed, Embase, Cochrane Library, CNKI, Wanfang, CBM, and ClinicalTrials.gov) until February 2024. The meta-analysis was performed using Stata 12. Outcomes were expressed in the form of standardized mean difference (SMD) and 95% confidence interval and were analyzed using meta-analysis.
The results showed that there was no significant difference in circulating visfatin levels between patients with MAFLD and controls (SMD = 0.13 [-0.34, 0.60]). However, the outcomes indicated that the level of circulating visfatin was significantly higher in MAFLD patients in the Middle Eastern subgroup (SMD = 0.45 [0.05, 0.85]) and in the obese patient subgroup (SMD = 1.05 [0.18, 1.92]). No publication bias was detected, and sensitivity analysis confirmed the stability of the outcomes.
The serum visfatin levels of MAFLD patients did not differ significantly from those of controls. However, visfatin concentrations in serum were statistically higher within Middle Eastern or obese MAFLD patients compared to controls. There is a need for further research to investigate visfatin's potential as a biomarker for MAFLD.
近年来，代谢相关脂肪性肝病（MAFLD）的发病率在全球范围内迅速上升，但早期诊断仍然是一个挑战。本系统评价和荟萃分析的目的是确定内脏脂肪素在 MAFLD 的早期诊断中的作用。
我们严格遵循系统评价和荟萃分析报告的首选条目指南的相关要求。系统检索了 7 个来源（PubMed、Embase、Cochrane Library、CNKI、万方、CBM 和 ClinicalTrials.gov），检索时间截至 2024 年 2 月。使用 Stata 12 进行荟萃分析。结果以标准化均数差（SMD）和 95%置信区间表示，并采用荟萃分析进行分析。
结果表明，MAFLD 患者和对照组之间循环内脏脂肪素水平没有显著差异（SMD=0.13[-0.34, 0.60]）。然而，结果表明，在中东亚组（SMD=0.45[0.05, 0.85]）和肥胖患者亚组（SMD=1.05[0.18, 1.92]）中，MAFLD 患者的循环内脏脂肪素水平显著升高。未发现发表偏倚，敏感性分析证实了结果的稳定性。
MAFLD 患者的血清内脏脂肪素水平与对照组无显著差异。然而，与对照组相比，中东或肥胖 MAFLD 患者的血清中内脏脂肪素浓度更高。需要进一步研究来探讨内脏脂肪素作为 MAFLD 生物标志物的潜力。
